Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AGER | Q15109 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357738 | 0.95 | ATM (0.56) | HPGDALDH1A1CYP1A2MAPK14POLB | |
| SCHEMBL5645103 | 0.89 | HPGD (0.62) | HPGDALDH1A1CYP1A2POLBNPC1 | |
| SCHEMBL5644455 | 0.88 | HPGD (0.52) | HPGDALDH1A1CYP1A2MAPK14POLB | |
| SCHEMBL6362683 | 0.85 | ATM (0.55) | HPGDATMSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL6362518 | 0.84 | ATM (0.58) | HPGDALDH1A1MAPK14NPC1RAB9A | |
| SCHEMBL6363231 | 0.83 | HDAC2 (0.52) | HPGDNPC1RAB9AATMKMT2A | |
| SCHEMBL6356671 | 0.83 | L3MBTL1 (0.57) | HPGDALDH1A1MAPK14ATMMAPT | |
| SCHEMBL6358381 | 0.82 | ATM (0.50) | ATMSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL6362552 | 0.81 | HPGD (0.57) | HPGDALDH1A1CYP1A2ATMKMT2A | |
| SCHEMBL6361631 | 0.81 | HPGD (0.54) | HPGDALDH1A1CYP1A2POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | HPGD 586/4885ALDH1A1 1194/4885CYP1A2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.